An older woman with glasses sits on a couch with knee pain

Sanofi is developing a new oral anti-inflammatory medication for treating rheumatoid arthritis and psoriasis.

credit: iStock.com/AsiaVision

Sanofi sees promise in a pill for inflammatory conditions

Elizabeth Laws leads Sanofi’s inflammation and immunology development pipeline to test the first oral TNFR1 inhibitor for rheumatoid arthritis and psoriasis.
Adam Boros, PhD
| 4 min read
Register for free to listen to this article
Listen with Speechify
0:00
4:00

Inflammation is a critical way that the body fights off infectious agents, but when that inflammation gets out of control — as is the case in the autoimmune conditions rheumatoid arthritis (RA) and psoriasis — it causes a problem. In recent years, scientists have developed ways to treat both of these conditions; their efforts have greatly improved the quality of life for patients.

Elizabeth Laws is smiling while wearing a black suit and standing in front of a grey canvas.
Vice President and Department Head of Sanofi’s Immunology and Inflammation pipeline, Elizabeth Laws, leads her team in developing anti-inflammatory drugs for chronic inflammatory diseases.
CREDIT: Sanofi

“We've been in this really blessed era where a huge swath of innovations have happened. … [They have] really transformed something that had been once sort of like a death sentence to now really having good therapeutic options,” said Elizabeth Laws, the Vice President and Department Head of Immunology and Inflammation at Sanofi. But, she added, “There's still a lot of room for a safe, oral efficacious drug in this space.”

Laws and her team are developing therapies for chronic inflammatory diseases, including rheumatoid arthritis (RA) and psoriasis (1,2). In particular, Law oversees the clinical trials for a new oral tumor necrosis factor receptor 1 (TNFR1) inhibitor: SAR441566.

TNFR1 inhibitors block the activity of TNFR1, a receptor that plays a crucial role in the inflammatory response. When the pro-inflammatory cytokine TNF-alpha binds to TNFR1, it triggers a signaling cascade that leads to inflammation and tissue damage. By inhibiting TNFR1, these drugs interrupt this pathway, reducing inflammation and its associated symptoms. 

Currently, monoclonal antibodies that target TNF-alpha are used to treat various inflammatory diseases like RA and psoriasis. However, these biologics have limitations, such as the need for multiple injections and potential side effects including increased risk of infections and heart problems.

Sanofi recently completed a Phase 1 proof-of-mechanism clinical trial for SAR441566 to treat psoriasis. The novel TNFR1 inhibitor was well-tolerated and clinically effective in patients with mild to moderate psoriasis. The company is now recruiting patients for a Phase 2 dose-finding study in patients with moderate to severe RA. Laws and her team hope that this oral medication may offer an alternative to existing medications that are less effective and require multiple injections.  

How did Sanofi begin developing inflammatory therapeutics?

At Sanofi, our mission is to improve patient lives for chronic, debilitating inflammatory diseases. Over the past 20 years, we have unlocked the biology of these different diseases, for example the role that different cytokines play in the inflammatory pathway and their interdependencies. What we have tried to do as a company is to pursue and build a robust pipeline around these targeted therapies. 

This was the “Holy Grail” we were chasing — the first oral formulation of a TNFR1 inhibitor.
- Elizabeth Laws, Sanofi  

Why are TNFR1 inhibitors an attractive drug target?

Every company is looking for a safe oral TNFR1 small molecule inhibitor. These drugs can also modulate T regulatory cells and keep the brakes on the inflammatory system. Historically, this has been done with immunosuppressants, but this systemically downregulates inflammation. Glucocorticosteroids are an example of these, but they have adverse side effects, so people can’t take them long term. The pharmaceutical industry is now going after TNFR1 inhibitors for more specificity to treat these conditions. 

What has the development process been like for this compound? 

Developing an oral drug is always complicated, and it's been in development for many years. We have had a large number of initial candidates that have undergone preclinical testing. Then, we must refine the formulation to ensure efficient manufacturing and that people can take it as a pill. We're excited for this one because it's actually met that high bar. It's really difficult to get something through all of that criteria. It's been many years in the works and lots of blood, sweat, and tears to get to this moment.

How did you feel when you saw positive results both from RA and psoriasis Phase I clinical trials?

When our team first saw the results, we were very excited. This was the “Holy Grail'' we were chasing — the first oral formulation of a TNFR1 inhibitor. Ten years ago, we were still unsure of this technology. Now, we are close to solving this puzzle. Results from our Phase 1 trials show that the formulation is safe and well tolerated in small patient cohorts.

How else could this technology be used? 

Oral medications are easy to combine with other therapies, which makes them easier for people to take compared to having multiple injections. People wouldn’t need to go to a medical office for repeated visits. We have some ideas, such as combining oral TNFR1 inhibitors with other advanced therapies that can boost their anti-inflammatory effect. A lot of inflammatory diseases are comorbid, so by treating both comorbidities at one time, we could boost overall outcomes. 

This interview has been condensed and edited for clarity.

References

  1. Vugler, A. et al. An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis. Front Pharmacol  13, 1037983 (2022).
  2. Fishbein, A. et al. The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis. CR Convergence 2023, Abstract 0443. https://acrabstracts.org/abstract/the-potential-of-an-oral-tnfα-inhibitor-with-tnfr1-specificity-results-of-a-phase-1b-proof-of-mechanism-trial-in-psoriasis/

About the Author

  • Adam Boros, PhD
    He earned his MSc and PhD degrees from the Faculty of Medicine at the University of Toronto and has extensive writing experience in the pharmaceutical industry.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue